Condensed Consolidated Statements Of Operations (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
REVENUES:
Net pharmaceutical product sales	$ 527,563	$ 394,121	$ 1,033,347	$ 754,470
Device, service and other revenues	80,048	2,403	134,290	6,466
TOTAL REVENUES	607,611	396,524	1,167,637	760,936
COSTS AND EXPENSES:
Cost of revenues	236,697	107,216	468,255	201,289
Selling, general and administrative	178,133	133,251	337,519	266,586
Research and development	40,840	44,656	82,970	73,824
Impairment of other intangible assets		13,000		13,000
Acquisition-related items	17,626	4,796	23,699	6,325
OPERATING INCOME	134,315	93,605	255,194	199,912
INTEREST EXPENSE, NET	25,560	9,984	44,350	19,788
LOSS ON EXTINGUISHMENT OF DEBT, NET	8,548		8,548
OTHER INCOME, NET	(125)	(201)	223	(420)
Total consolidated income before income tax	100,332	83,822	202,073	180,544
INCOME TAX	32,780	32,362	66,226	68,729
CONSOLIDATED NET INCOME	67,552	51,460	135,847	111,815
Less: Net income attributable to noncontrolling interests	12,969		25,477
NET INCOME ATTRIBUTABLE TO ENDO PHARMACEUTICALS HOLDINGS INC.	$ 54,583	$ 51,460	$ 110,370	$ 111,815
NET INCOME PER SHARE:
Basic net income per share	$ 0.47	$ 0.44	$ 0.95	$ 0.96
Diluted net income per share	$ 0.44	$ 0.44	$ 0.91	$ 0.95
WEIGHTED AVERAGE SHARES:
Basic	116,663	116,060	116,509	116,704
Diluted	122,686	116,660	121,724	117,346